Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corcept Therapeutics Inc. (CORT) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-powered summaries that help explain their contents. Corcept is a Nasdaq-listed, commercial-stage pharmaceutical company focused on cortisol modulation in endocrinologic, oncologic, metabolic and neurologic disorders, and its filings offer detailed insight into this business.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Corcept describes its commercial activities with Korlym, which it identifies as the first FDA-approved medication for patients with endogenous hypercortisolism, as well as its research and development programs in hypercortisolism, solid tumors, ALS and liver disease. These periodic reports typically discuss product revenue, research and development spending, and risks related to drug development and regulation.
Current reports on Form 8-K, some of which are summarized in the data provided, disclose material events such as quarterly financial results, submission and FDA acceptance of New Drug Applications for relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application to the European Medicines Agency, and the receipt of an FDA Complete Response Letter for relacorilant in hypertension secondary to hypercortisolism. Other 8-K filings describe corporate developments, including changes to distribution agreements for Korlym and board-level changes accompanied by consulting arrangements.
On this page, users can review Corcept’s Forms 10-K, 10-Q and 8-K as they are made available from EDGAR, while AI-generated highlights point out key topics such as clinical trial updates, regulatory milestones, revenue trends and significant contracts. The filings section also surfaces exhibits referenced in 8-Ks, helping investors and researchers understand how Corcept’s cortisol-modulation strategy, pipeline progress and commercial operations are reflected in its official regulatory reporting.
Corcept Therapeutics’ Chief Executive Officer Joseph K. Belanoff reported an open-market sale of 26,198 shares of common stock at a weighted average price of $50.0735 per share. The trade was executed indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust.
The sale occurred under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024. Following this transaction, the trust-related holdings reported for Belanoff total 2,918,326 shares of Corcept Therapeutics common stock.
The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A reporting 0 shares of Corcept Therapeutics Inc. common stock. The amendment states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report holdings separately under SEC Release No. 34-39538.
The filing lists amount beneficially owned: 0 and percent of class: 0%, and is signed by Ashley Grim on 03/26/2026. The Vanguard Group indicates no single other person holds more than 5% of the reported securities.
Corcept Therapeutics reported that the U.S. Food and Drug Administration has approved its drug Lifyorli (relacorilant), used with nab-paclitaxel, to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior bevacizumab-containing regimens.
The approval is based on the pivotal ROSELLA trial in 381 patients, where Lifyorli plus nab-paclitaxel cut the risk of death by 35 percent (hazard ratio 0.65; p=0.0004) and improved median overall survival to 16.0 months, versus 11.9 months with nab-paclitaxel alone. It also reduced the risk of disease progression by 30 percent (hazard ratio 0.70; p=0.008).
Lifyorli is described as the first FDA-approved selective glucocorticoid receptor antagonist and showed a manageable safety profile, though prescribing information carries warnings for neutropenia, severe infections, adrenal insufficiency, exacerbation of glucocorticoid-treated conditions and embryo-fetal toxicity, with common side effects including low blood counts, fatigue, nausea, diarrhea, rash and decreased appetite.
Corcept Therapeutics director James N. Wilson reported a bona fide gift of 4,000 shares of Common Stock. The gift was made at no stated price by the James N. Wilson and Pamela D. Wilson Trust, an entity through which he holds shares indirectly. Following this transaction, that trust holds 1,102,532 shares, with additional indirect holdings reported through a family partnership and two 2025 grantor retained annuity trusts.
Corcept Therapeutics Chief Development Officer William Guyer exercised stock options for 11,767 shares of common stock at $21.65 per share and on the same day sold 11,767 shares at a weighted average price of $36.01 per share. The sale prices ranged from $35.97 to $36.24 per share and was carried out under a Rule 10b5-1 trading plan adopted on November 27, 2024. Following these transactions, he directly holds 2,231 shares of common stock, plus 224 shares and 498 shares underlying unvested restricted stock awards that are scheduled to vest in full on the one-year anniversaries of their December 1, 2025 and March 2, 2026 grant dates, respectively, subject to specified conditions. The option exercised for 11,767 shares was fully exercisable before this transaction.
Corcept Therapeutics director Leonard G. Baker Jr. reported buying a total of 100,000 shares of Common Stock in open-market transactions on March 17, 2026. The purchases were split between 75,782 shares at a weighted average price of $33.0022 and 24,218 shares at a weighted average price of $33.5633, with actual trade prices ranging from $32.43 to $33.68.
Following these purchases, Baker directly holds 1,146,631 Corcept shares. He also has indirect interests in 3,308,303 shares held by a limited partnership and 1,095,262 shares held by a trust, while disclaiming beneficial ownership except to the extent of his pecuniary interests.
Director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, made a bona fide gift of 28,000 shares of Corcept Therapeutics common stock on March 13, 2026, with no cash changing hands. The filing shows that, after this gift, the trust held 1,106,532 shares, while the James and Pamela Wilson Family Partners entity held 901,067 shares, and each of two 2025 Grantor Retained Annuity Trusts held 200,000 shares. Wilson has voting power over the trust and family partnership holdings but disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
Corcept Therapeutics director David L. Mahoney reported a series of routine equity transactions. He exercised stock options covering 30,000 shares of Common Stock at $5.86 per share, converting a derivative position into directly held shares.
To cover the exercise price through a net, cashless exercise, 5,469 shares were withheld at a value of $32.15 per share, which is a tax/payment mechanism rather than an open-market sale. The remaining 24,531 shares were transferred as a bona fide gift to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust and are now reported as indirectly owned.
After these transactions, Mahoney reports 1,237,145 shares of Common Stock held indirectly through the family trust and an additional 46,147 shares held indirectly through The Black Dog Private Foundation. The filing shows no open-market purchases or sales of Corcept Therapeutics stock.
Corcept Therapeutics’ Chief Development Officer William Guyer exercised 8,233 stock options and sold the resulting shares. On March 4, 2026, he exercised options for 8,233 shares of common stock at an exercise price of $21.65 per share and then sold 8,233 shares in the open market at a weighted average price of $35.9949 per share, with individual sale prices ranging from $35.97 to $36.05. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024. After these transactions, Guyer held 2,231 shares of common stock directly, as well as options and restricted stock awards, including 224 and 498 shares underlying unvested restricted stock awards that vest on the one-year anniversaries of their respective grant dates, subject to specified conditions.